Resource

Letter to FDA Re: Supplements Marketed as Opioid Withdrawal Aids

ShareThis
Mitadone Anti-Opiate Aid Plus is one of the brands marketed online that CSPI investigated.

CSPI writes Scott Gottlieb, FDA Commissioner, and Steven Tave, Director of the FDA Office of Dietary Supplement Program urging the agency to take enforcement action to protect consumers from dietary supplements that are marketed as opioid withdrawal aids.